Patients | Form of II | Prominent sign | Alitretinoin’ efficacy on the prominent sign | Dosage of AL at the time of the final VAS evaluation (mg/day) | Global efficacy | VAS Scale (0-10) Before - during AL | VAS erythema (0-10) Before - during AL | VAS Palmoplantar keratoderma (0-10) Before - During AL | VAS Ectropion (0-10) Before - During AL |
---|---|---|---|---|---|---|---|---|---|
1 | LI | S | Low | 10 | Low | 5-7 | 0-0 | 4-4 | 0-0 |
2 | LI | E | High | 10 | High | 5-3 | 5-1 | 2-2 | 0-0 |
3 | LI | S | Low | 10 | Low | 5-7 | 0-0 | 4-4 | 0-0 |
4 | LI | S | Moderate | 30 | Moderate | 5-3 | 0-0 | 3-2 | 0-0 |
5 | LI | E | Moderate | 30 | Moderate | 5-4 | 6- | 1-1 | 0-0 |
6 | NS | E | High | 30 | High | 6-4 | 8-3 | 3-2 | 0-0 |
7 | CIE | E | Moderate | 10 | Moderate | 4-3 | 7-5 | 4-4 | 0-0 |
8 | CIE | E | Moderate | 30 | Moderate | 3-3 | 5-3 | 2-2 | 0-0 |
9 | CIE | E | Moderate | 30 | Moderate | 5-4 | 7-5 | 9-8 | 4-4 |
10 | KLICK | E | Moderate | 10 | Moderate | 4-3 | 6-4 | 5-4 | 0-0 |
11 | LI | S | Moderate | 30 | Moderate | 9-7 | 2-1 | 6-5 | 8-8 |
12 | LI | S | Moderate | 20 | Moderate | 9-7 | 2-2 | 6-5 | 8-7 |
13 | EK | E | Moderate | 30 | Moderate | 7-7 | 6-4 | 6-5 | 0-0 |